This week in therapeutics

Indication	Target/marker/ pathway	Summary	Licensing status	Publication and contact information
Endocrine disease				
Diabetes	Killer cell immunoglobulin-like receptor three domains long cytoplasmic tail 1 (KIR3DL1; KIR; CD158E1)	Studies in mice suggest that downregulating KIR3DL1 in T_{reg} cells prior to cellular immunotherapy could help treat type 1 diabetes. In prediabetic mice, adoptive transfer of T_{reg} cells with depleted *Kir3dl1* delayed the onset and decreased the incidence of type 1 diabetes compared with transfer of nondepleted T cells. Next steps include determining whether human KIR3DL1 has a similar role in regulating T cell function. *SciBX* 4(5); doi:10.1038/scibx.2011.130 Published online Feb. 3, 2011	Unpatented; licensing status not applicable	Qin, H. *et al. Proc. Natl. Acad. Sci. USA*; published online Jan. 17, 2011; doi:10.1073/pnas.1019082108 **Contact:** Chih-Pin Liu, Beckman Research Institute at City of Hope, Duarte, Calif. e-mail: cpliu@coh.org **Contact:** Arthur D. Riggs, same affiliation as above e-mail: ariggs@coh.org